News from regado biosciences, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Mar 20, 2014, 07:30 ET

Regado Biosciences to Present at the 21st Annual Future Leaders in the Biotech Industry Conference

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of its...

Mar 12, 2014, 17:35 ET

Regado Biosciences Announces Year-End 2013 Financial Results and Corporate Highlights

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of its...

Mar 10, 2014, 07:30 ET

FDA Designates Regado's REG1 in PCI as a Fast Track Development Program

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the development of actively controllable therapeutics, today...

Mar 06, 2014, 07:30 ET

Regado Biosciences to Provide Year-End and Fourth Quarter 2013 Financial Results

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class,...

Mar 05, 2014, 07:30 ET

Regado Biosciences to Present at the 26th Annual ROTH Conference

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively...

Feb 13, 2014, 07:30 ET

Regado Biosciences, Inc., Announces FDA Acceptance of IND for REG2

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class,...

Feb 12, 2014, 07:30 ET

Regado Biosciences, Inc., Broadens Patent Family Protecting Core Technology

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class,...

Feb 04, 2014, 07:30 ET

Regado Biosciences to Present at the 16th Annual BIO CEO & Investor Conference

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class,...

Jan 31, 2014, 08:15 ET

Regado Biosciences Announces $20 Million Private Placement

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively...

Jan 29, 2014, 07:30 ET

Regado Biosciences, Inc., Demonstrates Safety of Early Sheath Removal in Patients Treated with REG1 in Phase 2b Study

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class,...

Dec 17, 2013, 07:30 ET

Regado Biosciences, Inc. Adds World-Class Interventional Cardiologist and Researcher to Medical Advisory Board

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class,...

Dec 09, 2013, 07:30 ET

Regado Biosciences Strengthens Executive Leadership

  Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its...

Dec 06, 2013, 16:30 ET

Regado Biosciences, Inc. to Present at Oppenheimer's 24th Annual Healthcare Conference

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively...

Nov 18, 2013, 16:50 ET

Regado Biosciences, Inc. Adds Global Pharmaceutical Business Veteran to Board of Directors

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class,...

Nov 07, 2013, 07:30 ET

Regado Biosciences, Inc. Announces Third Quarter 2013 Results

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class,...

Nov 05, 2013, 17:01 ET

Regado Biosciences, Inc. Appoints World-Renowned Leader in Cardiovascular Research and Former Global Head of Cardiovascular Diseases for Merck & Co., to Board of Directors

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively...

Oct 31, 2013, 16:01 ET

Regado Biosciences, Inc. to Provide Third Quarter 2013 Financial Results

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class,...

Oct 02, 2013, 08:00 ET

Regado Biosciences, Inc. to Present at BIO Investor Forum

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class,...

Sep 25, 2013, 08:30 ET

Regado Biosciences, Inc. to Present at Aegis Capital Vegas Healthcare Conference

 Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class,...

Sep 17, 2013, 06:45 ET

Regado Biosciences, Inc. Enrolls First Patient in Phase 3 Trial of REG1

Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the discovery and development of novel, first-in-class, actively...